Sanofi, one of the three major insulin makers in the US, has announced a 78% reduction in the list price of its most widely prescribed insulin, Lantus, and a $35 monthly cap for those with private insurance. Uninsured Americans are eligible for Sanofi’s Insulins Valyou Savings Program. President Joe Biden praised the move, and Eli Lilly and Novo Nordisk have also announced changes to how they price their insulin this month. The Inflation Reduction Act and the actions of the three major insulin makers are a step in the right direction to make insulin more accessible and affordable for people with diabetes.
Posts tagged as “The Inflation Reduction Act”
House Republicans have proposed a plan to tackle the debt ceiling and roll back President Joe Biden's Inflation Reduction Act, which has been met with criticism from both sides of the aisle. The proposal, which is unlikely to become law, includes cutting student debt relief, Covid-19 funds, climate change funding, and capping discretionary spending. White House Press Secretary Jen Psaki has said the proposal "would be a major step backward for the American people and our economy."
Eli Lilly & Co. announced Wednesday that it will reduce prices for some of its older insulins and expand a cap on costs insured patients pay when they fill prescriptions, providing critical relief to people with diabetes who can face annual costs of more than $1,000 for insulin. The drugmaker said the cap on out-of-pocket costs will take effect immediately, though the high cost of insulin in the U.S. is still a major issue.
The White House has issued its first veto threat of the new Congress, targeting a House Republican bill that would rescind funding allotted to the…